Inventor
VALENZUELA DAVID M
US87 patents
⚠️ This page may combine multiple inventors who share the name “VALENZUELA DAVID M”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
44 patentsUS6586251B2Jul 1, 2003
Methods of modifying eukaryotic cells
REGENERON PHARMA505 citations99
US9228208B2Jan 5, 2016
Methods and compositions for the targeted modification of a genome
REGENERON PHARMA79 citations98
US8697851B2Apr 15, 2014
MiRNA-regulated differentiation-dependent self-deleting cassette
REGENERON PHARMA91 citations98
US7659442B2Feb 9, 2010
Method for making homozygous genetic modifications
REGENERON PHARMA239 citations98
US7576259B2Aug 18, 2009
Method for making genetic modifications
REGENERON PHARMA236 citations98
US7294754B2Nov 13, 2007
Method for generating an animal homozygous for a genetic modification
REGENERON PHARMA445 citations98
US7205148B2Apr 17, 2007
Genome mutation by intron insertion into an embryonic stem cell genome
REGENERON PHARMA93 citations98
US8354389B2Jan 15, 2013
miRNA-regulated differentiation-dependent self-deleting cassette
REGENERON PHARMA56 citations97
US10385359B2Aug 20, 2019
Targeted modification of rat genome
REGENERON PHARMA29 citations94
US10208317B2Feb 19, 2019
Methods and compositions for the targeted modification of a mouse embryonic stem cell genome
REGENERON PHARMA15 citations94
US9546384B2Jan 17, 2017
Methods and compositions for the targeted modification of a mouse genome
REGENERON PHARMA31 citations94
US10329582B2Jun 25, 2019
Genetic modification of rats
REGENERON PHARMA25 citations93
US9708635B2Jul 18, 2017
Methods of making a nucleic acid encoding a human variable region
REGENERON PHARMA9 citations93
US9388446B2Jul 12, 2016
Methods of producing hybrid antibodies
REGENERON PHARMA6 citations93
US9371553B2Jun 21, 2016
Genetically modified mice that produce hybrid antibodies
REGENERON PHARMA6 citations93
US9353394B2May 31, 2016
Methods of producing hybrid antibodies
REGENERON PHARMA6 citations93
US8846402B2Sep 30, 2014
Method for genetically modifying isolated non-human mammalian cell by homologous recombination
REGENERON PHARMA17 citations93
US10039269B2Aug 7, 2018
Methods and compositions for generating a mouse
REGENERON PHARMA10 citations92
US9730434B2Aug 15, 2017
Methods and compositions for generating a mouse
REGENERON PHARMA11 citations92
US9414575B2Aug 16, 2016
Methods and compositions for generating a mouse
REGENERON PHARMA12 citations92
US8946505B2Feb 3, 2015
Promoter-regulated differentiation-dependent self-deleting cassette
REGENERON PHARMA10 citations92
US8946504B2Feb 3, 2015
Promoter-regulated differentiation-dependent self-deleting cassette
REGENERON PHARMA10 citations92
US6852838B2Feb 8, 2005
Tyrosine kinase receptors and ligands
REGENERON PHARMA15 citations92
US5851797ADec 22, 1998
Tie ligand-3, methods of making and uses thereof
REGENERON PHARMA26 citations92
US5814478ASep 29, 1998
Tyrosine kinase receptors and ligands
REGENERON PHARMA20 citations92
US9738897B2Aug 22, 2017
Nuclease-mediated DNA assembly
REGENERON PHARMA13 citations91
US6610510B1Aug 26, 2003
Morphogenic proteins
REGENERON PHARMA20 citations91
US10711280B2Jul 14, 2020
Methods and compositions for the targeted modification of a mouse ES cell genome
REGENERON PHARMA5 citations84
US10640800B2May 5, 2020
Mice that produce hybrid antibodies
REGENERON PHARMA4 citations84
US10526630B2Jan 7, 2020
Genetically modified mice that produce hybrid antibodies
REGENERON PHARMA3 citations84
US10378038B2Aug 13, 2019
Mice that produce hybrid antibodies
REGENERON PHARMA3 citations84
US10378039B2Aug 13, 2019
Mouse embryonic stem cells comprising a hybrid heavy chain immunoglobulin locus
REGENERON PHARMA3 citations84
US10378040B2Aug 13, 2019
Mice that produce hybrid antibodies
REGENERON PHARMA4 citations84
US10378037B2Aug 13, 2019
Methods of making a nucleic acid encoding a human variable region
REGENERON PHARMA3 citations84
US10301646B2May 28, 2019
Nuclease-mediated targeting with large targeting vectors
REGENERON PHARMA12 citations84
US10227625B2Mar 12, 2019
Methods of modifying eukaryotic cells
REGENERON PHARMA3 citations84
US9834786B2Dec 5, 2017
Nuclease-mediated targeting with large targeting vectors
REGENERON PHARMA13 citations84
US9528136B2Dec 27, 2016
Methods of modifying eukaryotic cells
REGENERON PHARMA5 citations84
US9410163B2Aug 9, 2016
Promoter-regulated differentiation-dependent self-deleting cassette
REGENERON PHARMA3 citations84
US9382567B2Jul 5, 2016
Methods of producing hybrid antibodies
REGENERON PHARMA3 citations84
US10106820B2Oct 23, 2018
Methods and compositions for modifying a targeted locus
REGENERON PHARMA6 citations83
US9902971B2Feb 27, 2018
Methods for producing a mouse XY embryonic (ES) cell line capable of producing a fertile XY female mouse in an F0 generation
REGENERON PHARMA5 citations83
US9267152B2Feb 23, 2016
MiRNA-regulated differentiation-dependent self-deleting cassette
REGENERON PHARMA4 citations83
US9096870B2Aug 4, 2015
miRNA-regulated differentiation-dependent self-deleting cassette
REGENERON PHARMA6 citations83
MURPHY ANDREW J
2 patentsECONOMIDES ARIS N
1 patentFRENDEWEY DAVID
1 patentPOUEYMIROU WILLIAM
1 patentONCOGENE SCIENCE INC
1 patentShowing the top 50 of 87 patents by PatentIndex Score.